Kevin ten Haaf

List of Publications by Citations

44 papers	2,766 citations	22 h-index	52 g-index
54 ext. papers	4,054 ext. citations	9.6 avg, IF	5.16 L-index

#	Paper	IF	Citations
44	Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. *New England Journal of Medicine*, **2020**, 382, 503-513	59.2	734
43	Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*, **2014**, 160, 311-20	8	304
42	Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. *Lancet Oncology, The*, **2014**, 15, 1332-41	21.7	285
41	Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. *Lancet Oncology, The*, **2014**, 15, 1342-50	21.7	201
40	Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. *Thorax*, **2017**, 72, 48-56	7.3	139
39	Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. *Lancet Oncology, The*, **2016**, 17, 907-916	21.7	130
38	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. *PLoS Medicine*, **2017**, 14, e1002277	11.6	129
37	PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. *Journal of Thoracic Oncology*, **2018**, 13, S185	8.9	115
36	Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. *PLoS Medicine* , **2017**, 14, e1002225	11.6	69
35	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. *Cancer*, **2014**, 120, 1713-24	6.4	55
34	Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 154-61	4	53
33	Lung cancer screening: latest developments and unanswered questions. *Lancet Respiratory Medicine,the*, **2016**, 4, 749-761	35.1	51
32	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. *JAMA - Journal of the American Medical Association*, **2021**, 325, 988-997	27.4	44
31	Risk stratification based on screening history: the NELSON lung cancer screening study. *Thorax*, **2017**, 72, 819-824	7.3	40
30	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. *Annals of Internal Medicine*, **2019**, 171, 796-804	8	36
29	Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial. *JAMA Network Open*, **2019**, 2, e190204	10.4	35
28	Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. *PLoS ONE*, **2014**, 9, e99978	3.7	33

27	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. *Journal of the National Cancer Institute*, **2020**, 112, 466-479	9.7	32
26	Overdiagnosis in lung cancer screening: why modelling is essential. *Journal of Epidemiology and Community Health*, **2015**, 69, 1035-9	5.1	26
25	Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study. *Lung Cancer*, **2018**, 121, 61-69	5.9	25
24	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. *International Journal of Cancer*, **2017**, 140, 2436-2443	7.5	23
23	Disparities of National Lung Cancer Screening Guidelines in the US Population. *Journal of the National Cancer Institute*, **2020**, 112, 1136-1142	9.7	23
22	Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the Methodology. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	22
21	Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States. *Annals of the American Thoracic Society*, **2020**, 17, 186-194	4.7	21
20	Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening Study. *Journal of Thoracic Oncology*, **2015**, 10, 747-753	8.9	20
19	Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?. *Journal of Thoracic Oncology*, **2015**, 10, 1285-1291	8.9	20
18	All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study. *Cancer Medicine*, **2019**, 8, 6127-6138	4.8	17
17	Treatment capacity required for full-scale implementation of lung cancer screening in the United States. *Cancer*, **2019**, 125, 2039-2048	6.4	13
16	Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study. *Thorax*, **2019**, 74, 247-253	7.3	13
15	Personalising lung cancer screening: An overview of risk-stratification opportunities and challenges. *International Journal of Cancer*, **2021**, 149, 250-263	7.5	9
14	Low dose CT screening for lung cancer. *BMJ, The*, **2017**, 359, j5742	5.9	6
13	Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates. *Lung Cancer*, **2020**, 139, 200-206	5.9	6
12	Implementation of lung cancer screening: what are the main issues?. *Translational Lung Cancer Research*, **2021**, 10, 1050-1063	4.4	5
11	Extrapolation of pre-screening trends: Impact of assumptions on overdiagnosis estimates by mammographic screening. *Cancer Epidemiology*, **2016**, 42, 147-53	2.8	4
10	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. *JAMA Oncology*, **2021**,	13.4	4

9	Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer. *Pharmacoeconomics*, **2020**, 38, 1187-1200	4.4	4
8	Risk-Targeted Lung Cancer Screening. *Annals of Internal Medicine*, **2018**, 169, 199-200	8	2
7	Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 653-660	4	2
6	Methods for individualized assessment of absolute risk in case-control studies should be weighted carefully. *European Journal of Epidemiology*, **2016**, 31, 1067-1068	12.1	1
5	Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women. *JAMA Oncology*, **2021**, 7, 885-894	13.4	1
4	Risk-based lung cancer screening eligibility criteria: towards implementation.. *Lancet Oncology, The*, **2022**, 23, 13-14	21.7	0
3	Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses. *JAMA Oncology*, **2016**, 2, 277-8	13.4	
2	Confronting the burden of tobacco-related lung cancer in Europe in the next decades. *Lancet Regional Health - Europe, The*, **2021**, 4, 100085		
1	Re: Think before you leap. *International Journal of Cancer*, **2018**, 142, 1507-1509	7.5	